Company Description
Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastr...
Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors. It also develops two other clinical-stage drug candidates, DCC-3014 and rebastinib, as immuno-oncology kinase, inhibitors targeting the kinases CSF1R, and TIE2 kinas. The company was founded by Peter A. Petillo and Daniel L. Flynn in November 2003 and is headquartered in Waltham, MA.
Valuation
Price to Sales Ratio
5.90
Price to Book Ratio
1.88
Enterprise Value to EBITDA
-3.48
Enterprise Value to Sales
7.64
Efficiency
Total Asset Turnover
0.18
Liquidity
Current Ratio
3.50
Quick Ratio
3.36
Cash Ratio
2.95
Profitability
Gross Margin
90.23
Operating Margin
-284.85
Pretax Margin
-311.98
Net Margin
-311.98
Return on Assets
-55.97
Return on Equity
-70.71
Return on Total Capital
-60.16
Capital Structure
Total Debt to Total Assets
7.19
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Mr. Steven L. Hoerter | 50 | - | President, Director & Chief Executive Officer |
Mr. Thomas P. Kelly | 50 | 2015 | Chief Financial Officer |
Dr. Matthew L. Sherman | 64 | 2019 | Chief Medical Officer & Executive Vice President |
Dr. Rodrigo Ruiz Soto | - | 2017 | Senior Vice President-Clinical Development |
Dr. Daniel L. Flynn | 66 | - | President, Chief Executive Officer & Director |
Insider Actions
01/17/2023 |
Daniel L. Flynn Chief Scientific Officer |
2,403 | Disposition at $21.24 per share. | 51,039 |
01/17/2023 |
Matthew L. Sherman EVP & Chief Medical Officer |
2,403 | Disposition at $21.24 per share. | 51,039 |
01/17/2023 |
Daniel C. Martin Chief Commercial Officer |
1,603 | Disposition at $21.24 per share. | 34,047 |
01/17/2023 |
Thomas P. Kelly Chief Financial Officer |
2,403 | Disposition at $21.24 per share. | 51,039 |
01/17/2023 |
Jama Pitman See Remarks |
1,603 | Disposition at $21.24 per share. | 34,047 |
10/03/2022 |
Matthew L. Sherman EVP & Chief Medical Officer |
2,587 | Disposition at $18.73 per share. | 48,454 |
06/16/2022 |
Daniel L. Flynn Chief Scientific Officer |
1,768 | Disposition at $10.75 per share. | 19,006 |
06/16/2022 |
Matthew L. Sherman EVP & Chief Medical Officer |
1,768 | Disposition at $10.75 per share. | 19,006 |
06/16/2022 |
Daniel C. Martin Chief Commercial Officer |
1,311 | Disposition at $10.75 per share. | 14,093 |
06/16/2022 |
Thomas P. Kelly Chief Financial Officer |
1,768 | Disposition at $10.75 per share. | 19,006 |
06/16/2022 |
Jama Pitman See Remarks |
1,298 | Disposition at $10.75 per share. | 13,953 |
04/29/2022 |
Brightstar Associates LLC |
1,478,978 | Acquisition at $10 per share. | 14,789,780 |
03/21/2022 |
Steven L. Hoerter President and CEO; Director |
3,150 | Derivative/Non-derivative trans. at $9.11 per share. | 28,696 |
02/16/2022 |
Daniel L. Flynn Chief Scientific Officer |
1,366 | Disposition at $9.05 per share. | 12,362 |
02/16/2022 |
Matthew L. Sherman EVP & Chief Medical Officer |
984 | Disposition at $9.05 per share. | 8,905 |
02/16/2022 |
Daniel C. Martin Chief Commercial Officer |
1,146 | Disposition at $9.05 per share. | 10,371 |
02/16/2022 |
Thomas P. Kelly Chief Financial Officer |
1,368 | Disposition at $9.05 per share. | 12,380 |
02/16/2022 |
Jama Pitman See Remarks |
1,146 | Disposition at $9.05 per share. | 10,371 |
01/18/2022 |
Daniel L. Flynn Chief Scientific Officer |
20,500 | Award at $0 per share. | 0 |
01/18/2022 |
Matthew L. Sherman EVP & Chief Medical Officer |
20,500 | Award at $0 per share. | 0 |
01/18/2022 |
Daniel C. Martin Chief Commercial Officer |
13,667 | Award at $0 per share. | 0 |
01/18/2022 |
Thomas P. Kelly Chief Financial Officer |
20,500 | Award at $0 per share. | 0 |
01/18/2022 |
Jama Pitman See Remarks |
13,667 | Award at $0 per share. | 0 |
12/15/2021 |
Daniel L. Flynn Chief Scientific Officer |
11,100 | Award at $0 per share. | 0 |
12/15/2021 |
Matthew L. Sherman EVP & Chief Medical Officer |
11,100 | Award at $0 per share. | 0 |
12/15/2021 |
Daniel C. Martin Chief Commercial Officer |
8,300 | Award at $0 per share. | 0 |
12/15/2021 |
Thomas P. Kelly Chief Financial Officer |
11,100 | Award at $0 per share. | 0 |
12/15/2021 |
Jama Pitman See Remarks |
8,300 | Award at $0 per share. | 0 |
10/04/2021 |
Matthew L. Sherman EVP & Chief Medical Officer |
2,659 | Disposition at $33.17 per share. | 88,199 |
05/03/2021 |
Michael D. Taylor Director |
300 | Disposition at $46.75 per share. | 14,025 |
05/03/2021 |
Michael D. Taylor Director |
7,700 | Disposition at $46.07 per share. | 354,739 |
05/03/2021 |
Michael D. Taylor Director |
5,646 | Derivative/Non-derivative trans. at $3.95 per share. | 22,301 |
05/03/2021 |
Michael D. Taylor Director |
2,354 | Derivative/Non-derivative trans. at $1.89 per share. | 4,449 |
MarketWatch News on DCPH
-
Deciphera Pharmaceuticals stock price target raised to $18 from $11 at Stifel Nicolaus
- Tomi Kilgore
-
Deciphera Pharmaceuticals downgraded to hold from buy at Truist
- Tomi Kilgore
-
Deciphera Pharmaceuticals downgraded to hold from buy at Stifel Nicolaus
- Tomi Kilgore
-
Deciphera Pharmaceuticals stock price target cut to $65 from $84 at Truist
- Tomi Kilgore
-
Deciphera Pharmaceuticals coverage resumed at Stifel with buy stock rating and $60 target price
- Tonya Garcia
-
Deciphera Pharmaceuticals started at buy with $75 stock price target at Stifel Nicolaus
- Tomi Kilgore
-
Callon, Fitbit, Genco Shipping, and Other 13D Filings
- Barron's Online
-
Deciphera Pharmaceuticals stock price target raised to $60 from $45 at SunTrust RH
- Tomi Kilgore
-
Deciphera Pharmaceuticals stock rockets 126% premarket after positive trial data for GIST treatment
- Tomi Kilgore
-
Deciphera Pharmaceuticals started at buy with $42 stock price target at Deutsche Bank
- Tomi Kilgore
-
Deciphera Pharmaceuticals started at outperform with $47 stock price target at Raymond James
- Tomi Kilgore
-
Deciphera Pharmaceuticals started at buy with $60 stock price target at SunTrust RH
- Tomi Kilgore
-
Deciphera Pharmaceuticals started at overweight with $30 stock price target at J.P. Morgan
- Tomi Kilgore
Other News on DCPH
-
10-Q: DECIPHERA PHARMACEUTICALS, INC.
- Edgar Online - (EDG = 10Q, 10K)
-
Deciphera Pharmaceuticals (DCPH) Presents at ESMO Congress 2022
- Seeking Alpha
-
Deciphera Pharmaceuticals Q2 2022 Earnings Preview
- Seeking Alpha
- Loading more headlines...